The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti- PD-L1 antibodies.La présente invention concerne des thérapies à triple combinaison avec des anticorps anti-TIGIT, des anticorps anti-PVRIG et des inhibiteurs de points de contrôle, comprenant des anticorps anti-PD-1 ou anti- PD-L1.